A comparison between adjuvant and delivering functions of iron oxide and calcium phosphate nanoparticles, using a model protein against Brucella melitensis.
{"title":"A comparison between adjuvant and delivering functions of iron oxide and calcium phosphate nanoparticles, using a model protein against <i>Brucella melitensis</i>.","authors":"Tahereh Goudarzi, Morteza Abkar, Mahdi Fasihi-Ramandi, Mohammadsaleh Peikar, Zahra Zamanzadeh","doi":"10.7774/cevr.2025.14.e3","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>Calcium phosphate (CaP) and iron oxide (IO) nanoparticles (NPs) are promising adjuvants and delivery systems for vaccination. Furthermore, it has been shown that the chimeric antigen TF/Bp26/Omp31 (TBO) is a good candidate for stimulating protection against virulent <i>Brucella melitensis</i>. Our aim in the present study was to compare the roles of CaP and IO NPs for induction of the immune response and protection against <i>B. melitensis</i> 16M by using the TBO antigen as a model protein.</p><p><strong>Materials and methods: </strong>The <i>tbo</i> gene was expressed in the bacterial host and was evaluated by SDS-PAGE and western blot. The recombinant TBO was loaded onto CaP (CaP/TBO) and IO (IO/TBO) NPs. CaP/TBO and IO/TBO NPs were administered subcutaneously.</p><p><strong>Results: </strong>Antibody levels showed that immunization with both CaP/TBO and IO/TBO NPs stimulated mixed Th1-Th2 immune responses. In addition, immunized mice were challenged with a virulent strain of <i>B. melitensis</i> 16M. Immunized mice with CaP/TBO NPs showed a higher degree of protection than vaccinated animals with IO/TBO NPs.</p><p><strong>Conclusion: </strong>Altogether, our results indicated that the CaP NPs are a potent adjuvant and delivery system for subcutaneously administered <i>Brucella</i> antigens.</p>","PeriodicalId":51768,"journal":{"name":"Clinical and Experimental Vaccine Research","volume":"14 1","pages":"67-76"},"PeriodicalIF":2.1000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11799579/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and Experimental Vaccine Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.7774/cevr.2025.14.e3","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/13 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Purpose: Calcium phosphate (CaP) and iron oxide (IO) nanoparticles (NPs) are promising adjuvants and delivery systems for vaccination. Furthermore, it has been shown that the chimeric antigen TF/Bp26/Omp31 (TBO) is a good candidate for stimulating protection against virulent Brucella melitensis. Our aim in the present study was to compare the roles of CaP and IO NPs for induction of the immune response and protection against B. melitensis 16M by using the TBO antigen as a model protein.
Materials and methods: The tbo gene was expressed in the bacterial host and was evaluated by SDS-PAGE and western blot. The recombinant TBO was loaded onto CaP (CaP/TBO) and IO (IO/TBO) NPs. CaP/TBO and IO/TBO NPs were administered subcutaneously.
Results: Antibody levels showed that immunization with both CaP/TBO and IO/TBO NPs stimulated mixed Th1-Th2 immune responses. In addition, immunized mice were challenged with a virulent strain of B. melitensis 16M. Immunized mice with CaP/TBO NPs showed a higher degree of protection than vaccinated animals with IO/TBO NPs.
Conclusion: Altogether, our results indicated that the CaP NPs are a potent adjuvant and delivery system for subcutaneously administered Brucella antigens.
期刊介绍：
Clin Exp Vaccine Res, the official English journal of the Korean Vaccine Society, is an international, peer reviewed, and open-access journal. It covers all areas related to vaccines and vaccination. Clin Exp Vaccine Res publishes editorials, review articles, special articles, original articles, case reports, brief communications, and correspondences covering a wide range of clinical and experimental subjects including vaccines and vaccination for human and animals against infectious diseases caused by viruses, bacteria, parasites and tumor. The scope of the journal is to disseminate information that may contribute to elaborate vaccine development and vaccination strategies targeting infectious diseases and tumors in human and animals. Relevant topics range from experimental approaches to (pre)clinical trials for the vaccine research based on, but not limited to, basic laboratory, translational, and (pre)clinical investigations, epidemiology of infectious diseases and progression of all aspects in the health related issues. It is published printed and open accessed online issues (https://ecevr.org) two times per year in 31 January and 31 July. Clin Exp Vaccine Res is linked to many international databases and is made freely available to institutions and individuals worldwide
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
